PURPOSE: The retinal pigment epithelium (RPE) and underlying Bruch's membrane undergo significant modulation during ageing. Progressive, age-related modifications of lipids and proteins by advanced glycation end products (AGEs) at this cell-substrate interface have been implicated in RPE dysfunction and the progression to age-related macular degeneration (AMD). The pathogenic nature of these adducts in Bruch's membrane and their influence on the overlying RPE remains unclear. This study aimed to identify alterations in RPE protein expression in cells exposed to AGE-modified basement membrane (AGE-BM), to determine how this "aged" substrate impacts RPE function and to map the localisation of identified proteins in ageing retina. METHODS: Confluent ARPE-19 monolayers were cultured on AGE-BM and native, non-modified BM (BM). Following 28-day incubation, the proteome was profiled using 2-dimensional gel electrophoresis (2D), densitometry and image analysis was employed to map proteins of interest that were identified by electrospray ionisation mass spectrometry (ESI MS/MS). Immunocytochemistry was employed to localise identified proteins in ARPE-19 monolayers cultured on unmodified and AGE-BM and to analyze aged human retina. RESULTS: Image analysis detected altered protein spot densities between treatment groups, and proteins of interest were identified by LC ESI MS/MS which included heat-shock proteins, cytoskeletal and metabolic regulators. Immunocytochemistry revealed deubiquitinating enzyme ubiquitin carboxyterminal hydrolase-1 (UCH-L1), which was upregulated in AGE-exposed RPE and was also localised to RPE in human retinal sections. CONCLUSIONS: This study has demonstrated that AGE-modification of basement membrane alters the RPE proteome. Many proteins are changed in this ageing model, including UCHL-1, which could impact upon RPE degradative capacity. Accumulation of AGEs at Bruch"s membrane could play a significant role in age-related dysfunction of the RPE.
PURPOSE: The retinal pigment epithelium (RPE) and underlying Bruch's membrane undergo significant modulation during ageing. Progressive, age-related modifications of lipids and proteins by advanced glycation end products (AGEs) at this cell-substrate interface have been implicated in RPE dysfunction and the progression to age-related macular degeneration (AMD). The pathogenic nature of these adducts in Bruch's membrane and their influence on the overlying RPE remains unclear. This study aimed to identify alterations in RPE protein expression in cells exposed to AGE-modified basement membrane (AGE-BM), to determine how this "aged" substrate impacts RPE function and to map the localisation of identified proteins in ageing retina. METHODS: Confluent ARPE-19 monolayers were cultured on AGE-BM and native, non-modified BM (BM). Following 28-day incubation, the proteome was profiled using 2-dimensional gel electrophoresis (2D), densitometry and image analysis was employed to map proteins of interest that were identified by electrospray ionisation mass spectrometry (ESI MS/MS). Immunocytochemistry was employed to localise identified proteins in ARPE-19 monolayers cultured on unmodified and AGE-BM and to analyze aged human retina. RESULTS: Image analysis detected altered protein spot densities between treatment groups, and proteins of interest were identified by LC ESI MS/MS which included heat-shock proteins, cytoskeletal and metabolic regulators. Immunocytochemistry revealed deubiquitinating enzyme ubiquitin carboxyterminal hydrolase-1 (UCH-L1), which was upregulated in AGE-exposed RPE and was also localised to RPE in human retinal sections. CONCLUSIONS: This study has demonstrated that AGE-modification of basement membrane alters the RPE proteome. Many proteins are changed in this ageing model, including UCHL-1, which could impact upon RPE degradative capacity. Accumulation of AGEs at Bruch"s membrane could play a significant role in age-related dysfunction of the RPE.
Authors: Curtis L Nordgaard; Kristin M Berg; Rebecca J Kapphahn; Cavan Reilly; Xiao Feng; Timothy W Olsen; Deborah A Ferrington Journal: Invest Ophthalmol Vis Sci Date: 2006-03 Impact factor: 4.799
Authors: Krista K Graven; Christopher Molvar; Jill S Roncarati; Brian D Klahn; Shawna Lowrey; Harrison W Farber Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-05 Impact factor: 5.464
Authors: J T Handa; N Verzijl; H Matsunaga; A Aotaki-Keen; G A Lutty; J M te Koppele; T Miyata; L M Hjelmeland Journal: Invest Ophthalmol Vis Sci Date: 1999-03 Impact factor: 4.799
Authors: L Smith-Thomas; J W Haycock; R Metcalfe; M Boulton; S Ellis; I G Rennie; P S Richardson; I Palmer; M A Parsons; S Mac Neil Journal: Curr Eye Res Date: 1998-08 Impact factor: 2.424
Authors: Sarah Warburton; Wayne E Davis; Katie Southwick; Huijun Xin; Adam T Woolley; Gregory F Burton; Craig D Thulin Journal: Mol Vis Date: 2007-03-01 Impact factor: 2.367
Authors: Josephine V Glenn; J Renwick Beattie; Lindsay Barrett; Norma Frizzell; Suzanne R Thorpe; Mike E Boulton; John J McGarvey; Alan W Stitt Journal: FASEB J Date: 2007-06-12 Impact factor: 5.191
Authors: Astrid Subrizi; Elisa Toropainen; Eva Ramsay; Anu J Airaksinen; Kai Kaarniranta; Arto Urtti Journal: Pharm Res Date: 2014-07-17 Impact factor: 4.200